内科理论与实践››2023,Vol. 18››Issue (03): 197-200.doi:10.16138/j.1673-6087.2023.03.013
张会健, 李贵森(
)
收稿日期:2022-09-15出版日期:2023-06-30发布日期:2023-08-07通讯作者:李贵森 E-mail:
基金资助:
ZHANG Huijian, LI Guisen()
Received:2022-09-15Online:2023-06-30Published:2023-08-07中图分类号:
张会健, 李贵森. IgA肾病补体靶向治疗研究进展[J]. 内科理论与实践, 2023, 18(03): 197-200.
ZHANG Huijian, LI Guisen. An update on complement targeted treatment of IgA nephropathy[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 197-200.
图1
补体系统及药物作用靶点 MBL：甘露聚糖结合凝集素（mannan-binding lectin）；MASP：MBL相关丝氨酸蛋白酶（MBL-associated serine protease）。
表1
补体靶向药物临床试验
| 靶点 | 药物名称 | 临床研究分期 | 状态 | 开始时间 | 试验ID |
|---|---|---|---|---|---|
| 补体C3的RNAi药物 | AROC3-1001 | 1/2a期 | 进行中 | 2022年2月 | NCT05083364 |
| C5aR抑制剂 | avacopan（CCX168） | 2期 | 完成 | 2015年2月 | NCT02384317 |
| C5抑制剂 | 瑞利珠单抗（ravulizumab） | 2期 | 进行中 | 2020年12月 | NCT04564339 |
| ALXN1720 | 1期 | 进行中 | 2022年5月 | NCT05314231 | |
| MASP-2抑制剂 | narsoplimab（OMS721） | 2期 | 完成 | 2016年2月 | NCT02682407 |
| 3期 | 进行中 | 2018年2月 | NCT03608033 | ||
| B因子抑制剂 | iptacopan（LNP023） | 2a/2b期 | 完成 | 2018年2月 | NCT03373461 |
| 3期 | 进行中 | 2021年1月 | NCT04578834 | ||
| 3期 | 进行中 | 2021年9月 | NCT04557462 | ||
| B因子反义抑制剂 | IONIS-FB-LRx | 2a期 | 进行中 | 2019年12月 | NCT04014335 |
| D因子抑制剂 | pelecopan（BCX9930） | 2期 | 进行中 | 2021年10月 | NCT05162066 |
| vemicropan（ALXN2050） | 2期 | 进行中 | 2022年1月 | NCT05097989 |
| [1] | Robert T, Jantzen R, Cambier A, et al. Spatiotemporal trends and prognosis of end-stage renal disease patients with biopsy-proven immunoglobulin A nephropathy in France from 2010 to 2014[J]. Clin Kidney J, 2021, 14(3):898-908. doi:10.1093/ckj/sfaa029URL |
| [2] | Schena FP, Nistor I. Epidemiology of IgA nephropathy:a global perspective[J]. Semin Nephrol, 2018, 38(5):435-442. doi:10.1016/j.semnephrol.2018.05.013URL |
| [3] | Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Long term outcome of immunoglobulin A (IgA) nephropathy: a single center experience[J]. PLoS One, 2021, 16(4): e0249592. doi:10.1371/journal.pone.0249592URL |
| [4] | Medjeral-Thomas NR, Cook HT, Pickering MC. Complement activation in IgA nephropathy[J]. Semin Immuno-pathol, 2021, 43(5): 679-690. |
| [5] | Poppelaars F, Faria B, Schwaeble W, et al. The contribution of complement to the pathogenesis of IgA nephropathy: are complement-targeted therapies moving from rare disorders to more common diseases?[J]. J Clin Med, 2021, 10(20):4715. doi:10.3390/jcm10204715URL |
| [6] | Wu L, Liu D, Xia M, et al. Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study[J]. BMC Nephrol, 2021, 22(1): 43. doi:10.1186/s12882-021-02237-wpmid:33514328 |
| [7] | Tan L, Tang Y, Pei G, et al. A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy[J]. Sci Rep, 2021, 11(1): 5467. doi:10.1038/s41598-021-84715-7pmid:33750830 |
| [8] | Wang Z, Jiang Y, Chen P, et al. The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: a cohort study[J]. Nephrol Dial Transplant, 2022, 37(11): 2119-2127. doi:10.1093/ndt/gfac024URL |
| [9] | Worawichawong S, Plumworasawat S, Liwlompaisan W, et al. Distribution pattern of mesangial C4d deposits as predictor of kidney failure in IgA nephropathy[J]. PLoS One, 2021, 16(6): e0252638. doi:10.1371/journal.pone.0252638URL |
| [10] | Eder M, Kozakowski N, Omic H, et al. Glomerular C4d in post-transplant IgA nephropathy is associated with decreased allograft survival[J]. J Nephrol, 2021, 34(3): 839-849. doi:10.1007/s40620-020-00914-xpmid:33306182 |
| [11] | Yeo SC, Liu X, Liew A. Complement factor H gene polymorphism rs6677604 and the risk, severity and progression of IgA nephropathy: a systematic review and meta-analysis[J]. Nephrology (Carlton), 2018, 23(12): 1096-1106. doi:10.1111/nep.2018.23.issue-12URL |
| [12] | Gyapon-Quast F, Goicoechea de Jorge E, Malik T, et al. Defining the glycosaminoglycan interactions of complement factor H-related protein 5[J]. J Immunol, 2021, 207(2): 534-541. doi:10.4049/jimmunol.2000072pmid:34193601 |
| [13] | Medjeral-Thomas NR, Lomax-Browne HJ, Beckwith H, et al. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy[J]. Kidney Int, 2017, 92(4): 942-952. doi:S0085-2538(17)30256-9pmid:28673452 |
| [14] | Jullien P, Laurent B, Claisse G, et al. Deletion variants of CFHR1 and CFHR3 associate with mesangial immune deposits but not with progression of IgA nephropathy[J]. J Am Soc Nephrol, 2018, 29(2): 661-669. doi:10.1681/ASN.2017010019URL |
| [15] | Paunas TIF, Finne K, Leh S, et al. Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy[J]. Clin Proteomics, 2017, 14: 30. doi:10.1186/s12014-017-9165-xURL |
| [16] | Zhu L, Guo WY, Shi SF, et al. Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy[J]. Kidney Int, 2018, 94(1): 150-158. doi:S0085-2538(18)30214-Xpmid:29759419 |
| [17] | Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy[J]. Semin Immunopathol, 2021, 43(5): 717-728. doi:10.1007/s00281-021-00888-3pmid:34495361 |
| [18] | Hu X, Feng J, Deng S, et al. Anaphylatoxins enhance Th9 cell recruitment via the CCL20-CCR6 axis in IgA nephropathy[J]. J Nephrol, 2020, 33(5): 1027-1036. doi:10.1007/s40620-020-00708-1 |
| [19] | Hu X, Feng J, Zhou Q, et al. Respiratory syncytial virus exacerbates kidney damages in IgA nephropathy miceviathe C5a-C5aR1 axis orchestrating Th17 cell responses[J]. Front Cell Infect Microbiol, 2019, 9: 151. doi:10.3389/fcimb.2019.00151URL |
| [20] | Lee A. Avacopan: first approval[J]. Drugs, 2022, 82(1): 79-85. doi:10.1007/s40265-021-01643-6 |
| [21] | Bruchfeld A, Magin H, Nachman P, et al. C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study[J]. Clin Kidney J, 2022, 15(5): 922-928. doi:10.1093/ckj/sfab294pmid:35498891 |
| [22] | Nakamura H, Anayama M, Makino M, et al. Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy[J]. Nephron, 2018, 138(4): 324-327. doi:10.1159/000485194URL |
| [23] | Guzzo G, Sadallah S, Fodstad H, et al. Case report: a rare truncating variant of the CFHR5 gene in IgA nephropathy[J]. Front Genet, 2021, 12: 529236. doi:10.3389/fgene.2021.529236URL |
| [24] | Herzog AL, Wanner C, Amann K, et al. First treatment of relapsing rapidly progressive IgA nephropathy with eculizumab after living kidney donation[J]. Transplant Proc, 2017, 49(7): 1574-1577. doi:10.1016/j.transproceed.2017.02.044URL |
| [25] | McKeage K. Ravulizumab: first global approval[J]. Drugs, 2019, 79(3): 347-352. doi:10.1007/s40265-019-01068-2pmid:30767127 |
| [26] | Barratt J, Carroll K, Lafayette R. Pos-107 long-term phase 2 efficacy of the masp-2 inhibitor narsoplimab for treatment of severe IgA nephropathy[J]. Kidney Int Rep, 2022, 7(2): S45. |
| [27] | Lafayette RA, Rovin BH, Reich HN, et al. Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy[J]. Kidney Int Rep, 2020, 5(11): 2032-2041. doi:10.1016/j.ekir.2020.08.003pmid:33163724 |
| [28] | Barratt J, Rovin B, Zhang H, et al. Pos-546 efficacy and safety of iptacopan in iga nephropathy: results of a randomized double-blind placebo-controlled phase 2 study at 6 months[J]. Kidney Int Rep, 2022. 7(2): S236. |
| [29] | Perkovic V, Rovin B, Zhang H, et al. A multi-center, randomized, double-blind, placebo controlled, parallel group, phase Ⅲ study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients[J]. Nephrol Dial Transplant, 2021, 36 Suppl 1:mo148. |
| [1] | 魏亚培 王婷婷 陈滢滢 张睿 郝昆.
胸导管探查术后综合消肿治疗对双下肢淋巴水肿患者的短期效果
[J]. 组织工程与重建外科杂志, 2023, 19(3): 249-. |
| [2] | 管亚芩 吴锦阳 余丽雅 张诗雷.
数字化手术设计流程在颌面部骨折整复治疗中的应用分析
[J]. 组织工程与重建外科杂志, 2023, 19(3): 289-. |
| [3] | 李新宇 郭智霖.
外伤性视神经损伤的研究进展
[J]. 组织工程与重建外科杂志, 2023, 19(3): 315-. |
| [4] | 邱煜程 周显玉 刘菲 杨军.
间充质干细胞及其外泌体在移植中的应用进展
[J]. 组织工程与重建外科杂志, 2023, 19(2): 184-. |
| [5] | 孙家园 侯瑞 张如鸿.
缺血再灌注损伤性皮瓣坏死的防治进展
[J]. 组织工程与重建外科杂志, 2023, 19(2): 193-. |
| [6] | 边巴拉吉 次旺加措 蔡磊 巴罗 周栩.
西藏地区保留局部皮瓣联合小剂量放疗治疗耳廓瘢痕疙瘩的临床研究
[J]. 组织工程与重建外科杂志, 2023, 19(1): 34-. |
| [7] | 高定辉, 陈勇, 王倩, 等. 肌内静脉畸形的影像学观察：单中心回顾性分析[J]. 组织工程与重建外科杂志, 2023, 19(1): 37-. |
| [8] | 刘井清, 林燕娴, 袁巍巍, 等.单次聚焦射频治疗皮肤型鼻唇沟凹陷的初步研究[J]. 组织工程与重建外科杂志, 2023, 19(1): 44-. |
| [9] | 陈娅, 周慧.血液肿瘤患者焦虑抑郁现状及与治疗信心的相关性研究[J]. 组织工程与重建外科杂志, 2023, 19(1): 59-. |
| [10] | 邓智中, 周显玉, 刘菲, 等.免疫抑制缓释用于治疗同种异体复合组织移植的研究进展[J]. 组织工程与重建外科杂志, 2023, 19(1): 79-. |
| [11] | 赖莉琴, 龚艳春.原发性醛固酮增多症慢性肾损伤的研究进展[J]. 内科理论与实践, 2023, 18(03): 211-214. |
| [12] | 徐凯, 李百文.早期胃癌及胃癌前病变的内镜黏膜下剥离术治疗[J]. 内科理论与实践, 2023, 18(02): 102-106. |
| [13] | 邢颖, 程石.胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114. |
| [14] | 高卫奇, 张旭, 王铮, 朱一霏, 黄佳慧, 洪进, 朱思吉, 陈小松, 黄欧, 何建蓉, 陈伟国, 李亚芬, 沈坤炜, 徐华, 吴佳毅.新辅助治疗后腹壁下深血管穿支皮瓣即刻乳房重建手术的安全性研究[J]. 外科理论与实践, 2023, 28(02): 147-151. |
| [15] | 王远江, 邹浩.胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
